Haizheng pharmaceutical: obtaining drug registration certificate for ticagrelor tablets

Haizheng pharmaceutical announced that the company received ticagrelor tablets approved and issued by the State Food and drug administration. Ticagrelor tablets are mainly used in the treatment of acute coronary syndrome and reduce the incidence of cardiovascular death, myocardial infarction and stroke in patients with ACS or with a history of myocardial infarction. 08/16/2020